Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Promoting Paraguayan stevia

This article was originally published in The Tan Sheet

Executive Summary

The U.S. Agency for International Development and stevia extract manufacturer PureCircle encourage stevia cultivation in southern Paraguay through a cooperation and mutual investment agreement with the Paraguayan government. USAID's Paraguay Vende economic growth program will assist PureCircle South America in developing a business plan and stevia production basins in the Itapua department. "This is a very significant development" for the stevia industry, said PureCircle VP of Supply Chain Dorn Wenninger Oct. 12. PureCircle, with a U.S. office in Oak Brook, Ill., further cited the "enormous commercial opportunities and socioeconomic benefits that stevia cultivation is bringing to South America." As stevia-based sweeteners grow in popularity, stakeholders say limited supply is a problem (1"The Tan Sheet" July 6, 2009)

You may also be interested in...

Supply's The Limit As Stevia-Based Sweeteners Gain In Popularity

Stevia-based sweetener marketers appear to have cleared the challenge of FDA acceptance, but face another in ensuring ready availability of South American stevia rebaudiana

Finance Watch: Two SPAC Deals, Two IPOs Take Four Biopharmas Public

Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.

#ClinicalTrialsSoWhite: How Drug Makers Are Using COVID-19 To Improve Trial Diversity

Efforts to improve trial diversity predate COVID-19, but the pandemic’s disproportionate effects on minority communities have brought the issue to the forefront.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts